Irene Agodoa, MD, on Assessing Orca-T for Safer Cell Therapy in Hematologic Malignancies

Video

The senior vice president and head of medical affairs at Orca Bio discussed the initiation of the Precision-T phase 3 trial.

“Orca Bio’s Precision-T study is a phase 3 randomized, multicenter study that's being conducted in the US. We are enrolling approximately 174 patients that are going to be randomized 1:1. One arm of patients will receive Orca-T and the other arm of patients will receive the standard of care allogeneic transplant.”

Orca Bio has initiated the phase 3 Precision-T clinical trial (NCT05316701) evaluating Orca-T, an allogeneic cell therapy, for the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and high-risk myelodysplastic syndromes (MDS).

Precision-T is comparing the safety and efficacy of Orca-T against standard of care allogeneic hematopoietic stem cell transplant (allo-HSCT). Orca-T has been developed with the intention of mitigating the risks of drawbacks to standard allo-HSCT including graft versus host disease (GVHD) and other transplant-related adverse events. The study will primarily be assessing the incidence of GVHD.

CGTLive spoke with Irene Agodoa, MD, senior vice president and head, medical affairs, Orca Bio, to learn more about the Precision-T study, which has begun dosing in centers around the US. She discussed the indications it is being assessed in as well as the origins of the therapy and the company.

REFERENCE
Orca Bio announces the Precision-T phase 3 study is open and enrolling patients at transplant centers across the US. News release. Orca Bio. August 2, 2022. https://orcabio.com/2022-08-02/

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.